Advanced Enzyme Q1 FY27 results: profit down 7.5% in 2026

What the company reported on August 8

Advanced Enzyme Technologies announced its first-quarter FY2026-27 results on Saturday, August 8. The Maharashtra-based enzyme maker reported net profit of ₹37 crore, down 7.5% from ₹40 crore in the comparable period of the previous year, as cited in the update. Revenue provided some relief, with the topline rising 2.2% to ₹190 crore from ₹186 crore.

Alongside the quarterly numbers, the board approved a share buyback and cleared a plan to acquire the remaining minority stake in an existing subsidiary. The stock ended the session lower after the announcements, even as it remained higher over a six-month period.

Revenue up, but profitability metrics weakened

While revenue growth was positive on a year-on-year basis, profitability indicators softened. The company said EBITDA declined 9.6% year-on-year to ₹51.1 crore from ₹56.5 crore. EBITDA margin also fell to 26.9% compared with 30.38% a year earlier.

The combination of a modest revenue increase and a sharper decline in EBITDA suggests cost pressures or an unfavourable operating mix during the quarter, based on the numbers disclosed. The company’s reported net profit decline broadly aligns with the softer operating performance.

Consolidated financial snapshot for the quarter ended June 30, 2026

The board approved the unaudited consolidated financial results for the quarter ended June 30, 2026. The results were reviewed by the statutory auditors, who expressed an unmodified conclusion.

On a consolidated basis, revenue from operations was reported at ₹189.79 crore (₹1,897.88 million), with net profit at ₹38.59 crore (₹385.89 million) for the quarter. Net profit attributable to shareholders of the company stood at ₹37.09 crore (₹370.93 million), while non-controlling interest was ₹1.50 crore (₹14.96 million).

Standalone performance numbers also disclosed

Advanced Enzyme also disclosed standalone results for the same quarter. Standalone revenue from operations stood at ₹115.86 crore (₹1,158.57 million), while standalone net profit was ₹22.35 crore (₹223.46 million).

The standalone disclosure also showed other income of ₹2.29 crore for Q1 FY27, compared with ₹53.85 crore in Q1 FY26. The company did not provide additional explanation for the change in other income within the supplied text, so the context should be read strictly as reported in the table.

Key financials table (figures in ₹ crore)

Board clears ₹69.7 crore buyback via open market

A key board decision was a share buyback of up to 13,94,000 equity shares at a maximum price of ₹500 per share. The aggregate buyback size was capped at ₹69.7 crore (₹697,000,000), to be executed via the open market route through the stock exchange mechanism.

The buyback will be conducted from shareholders other than promoters, the promoter group, and persons in control of the company. The approval was stated to be in accordance with the SEBI (Buy-Back of Securities) Regulations, 2018, and the Companies Act, 2013.

At the maximum buyback size and price, the indicative maximum number of shares to be bought back is 13,94,000, representing 1.24% of the existing paid-up equity capital, as disclosed. The maximum buyback size represents 9.99% and 5.09% of the aggregate of total paid-up equity share capital and free reserves based on the latest audited standalone and consolidated financial statements as on March 31, 2026, respectively.

Subsidiary move: JC Biotech to become wholly owned

The board also approved the acquisition of the remaining 4.28% equity shares of JC Biotech Private Limited from existing shareholders. JC Biotech was described as an existing subsidiary in which Advanced Enzyme holds 95.72%.

Upon completion of the transaction, JC Biotech will become a wholly owned subsidiary of the company, according to the disclosure. No purchase consideration or timeline details were provided in the supplied text.

Dividend and trading window details

The company had proposed a final dividend of ₹1.35 per equity share for FY2025-26. This dividend was approved by shareholders at the Annual General Meeting held on July 31, 2026, and was paid on August 5, 2026.

Separately, the company stated that the trading window for its securities would remain closed until August 10, 2026, in the run-up to the board meeting and results, as part of insider trading controls.

Stock market reaction and recent price performance

Advanced Enzyme Technologies shares closed lower by 1.79% (down ₹5.90) following the disclosures. The closing price cited was ₹323.90 per share.

Over the past six months, the stock price was reported to have risen 11.08%, indicating that the near-term reaction came after a period of gains. The supplied transcript also cited a P/E of 25.4 and a market capitalisation value of ₹4,073.

What investors will likely track next

For investors, the immediate focus is likely to be on the progression of the open-market buyback and any subsequent filings or operational disclosures that clarify execution timelines. Another area to watch is whether profitability metrics such as EBITDA margin stabilise after the year-on-year decline reported for the quarter.

The move to make JC Biotech a wholly owned subsidiary also becomes relevant from a consolidation and governance standpoint, because it removes the non-controlling minority stake at the subsidiary level. In the quarter’s consolidated results, non-controlling interest accounted for ₹1.50 crore of net profit, underscoring that minority interests were still present in the group structure.

Conclusion

Advanced Enzyme Technologies’ Q1 FY27 update combined softer profitability with modest revenue growth, while the board approved a ₹69.7 crore buyback and a plan to take full ownership of JC Biotech. The next set of disclosures will centre on buyback execution via the stock exchange route and completion of the subsidiary stake acquisition, as and when the company provides further details.